SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors react to a wave of bullish analyst upgrades, a major strategic AI chip deal with Meta, and ongoing community enthusiasm regarding the company's competitive positioning against rivals like NVIDIA. Traders are actively discussing the stock's recent momentum, with widespread debate over potential price breakouts toward the $300 level and the durability of the AI-driven data center growth cycle.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is surging on heavy volume as investors react to regulatory news regarding the potential easing of restrictions on peptide access, fueling speculation of a major short squeeze given the stock's significant short interest. The community is actively debating the sustainability of this rally, with many traders drawing parallels to past momentum runs and expressing strong conviction in the company's platform-driven growth strategy.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors bet on a potential short squeeze fueled by record-high short interest and anticipation surrounding the company's upcoming acquisition of Northern Data. The community is actively discussing the stock's long-term growth potential through cloud infrastructure expansion and the strategic backing of Tether, which remains a key catalyst for bullish sentiment.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings Limited (WSHP) is currently experiencing intense volatility and social media attention as traders monitor aggressive price swings often associated with low-float momentum plays. The community is actively debating the stock's potential for dramatic short squeezes while warning of the risks inherent in such speculative, high-volume trading activity.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a combination of high-volume momentum, a new contract with DARPA for the HARQ program, and positive sector sentiment sparked by Nvidia's launch of open-source quantum AI models. While community discourse remains polarizedwith bulls cheering the breakout and the potential for a short squeeze, and bears warning of fundamental weaknesses and valuation concernstraders are actively debating whether this is a sustainable sector rotation or a recurring short-term hype cycle.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently in the spotlight following an analyst upgrade to outperform and a significant capital raise that bolsters its balance sheet for future growth. The community is buzzing with excitement over the upcoming Neutron rocket launch, while ongoing discussions focus on the company's strategic acquisitions and its strengthening position within the aerospace and defense sectors as a prime contractor.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently experiencing significant volatility as the community debates a recent downgrade from Mizuho alongside conflicting reports regarding potential stakes from high-profile investors. Shareholders remain divided between frustration over prolonged price stagnation and bullish sentiment centered on the company's strong free cash flow and persistent share buybacks.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant market attention driven by high short interest and anticipation surrounding its upcoming earnings report. The community is actively discussing the potential for a short squeeze, fueled by the stock's recent volatility and strong retail interest in its voice-first AI technology.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing intense retail and algorithmic interest following a record-breaking production order for its AI chip burn-in technology, which has sparked a fierce tug-of-war between bullish investors citing long-term infrastructure demand and skeptics pointing to heavy insider selling and a recent share offering. Market participants are actively debating whether the stock is undergoing a genuine rerating as a critical AI hardware play or if the aggressive, high-volume price action is an overextended pump that is susceptible to a sharp technical correction.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community focus as traders debate the potential for a short squeeze amid high short interest and a perceived "bear trap" setup following a dip in share price. Investors are actively discussing the company's "Opendoor 2.0" turnaround strategy, specifically highlighting rising weekly home acquisition numbers and institutional confidence as catalysts that could drive a re-rating once the housing market stabilizes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows.</li><li>Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.&nbsp;</li><li>Processa develops drugs for life-threatening and life-compromising chronic diseases.</li></ul>Shares of Processa Pharmaceuticals, Inc. (PCSA) closed up 6% and edged up 10% after hours on Thursday after several insiders at the company, including the CEO, made share purchases.According to filings made with the Securities and Exchange Commission, several insiders including Director Baluch Khoso, Chief Development Officer Bigora Sian, Chief Administrative Officer Guy Wendy, Chief Business Strategy Officer Lin Patrick, Chief Executive Officer Ng George K, Director Pannu Geraldine, Chief Financial Officer Skibsted Russell, President of Research &amp; Development Young David all bought shares of the company at a price of about $2.535 on the last day of March.CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows. Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.<h2 class="st-heading-2">About Processa</h2>Processa develops drugs for life-threatening and life-compromising chronic diseases. Its pipeline includes NGC-Cap and NGC-Iri for the treatment of certain cancers, PCS12852 for gastroparesis and constipation disorders and PCS499 for primary glomerular diseases. While the company has completed early-to-mid stage studies for PCS12852 and PCS499, mid-stage trials are in process for NGC-Cap. NGC-Iri, meanwhile, is still in preclinical stages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PCSA stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.“Nice to see the little token insider purchases apparent "ploy" working just as designed. Predictable, like death and taxes,” a Stocktwits user wrote.<stembedurl>https://www.stocktwits.com/Jwa68/message/649316897</stembedurl>Another voiced optimism for the stock rallying up to $20.<stembedurl>https://www.stocktwits.com/Shallu/message/649328642</stembedurl><a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> has lost nearly 63% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lpcn-stock-crashes-heres-why/cZ7x6c9RI88">LPCN Stock Crashes 78%— Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PCSA Stock Rallies 10% After Hours— Here’s Why

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 

Equity

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 


PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.read more...

<ul class="summary-bullets"><li>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company announced that it is building an AI data center for Anthropic.</li><li>Processa Pharmaceuticals' shares were up nearly 95% after early Phase 2 data showed that its NGC-Cap therapy boosts capecitabine exposure without added side effects compared with standard treatment.</li><li>Recursion Pharmaceuticals shares jumped over 16% by midday Wednesday after Morgan Stanley upgraded the stock to ‘Overweight’ and raised its price target to $11, citing strong efficacy for its drug REC-4881.</li></ul>U.S. equities were in the red in Wednesday’s midday trade as investors exercised caution amid a broader decline in artificial intelligence stocks, with Oracle and Broadcom shares declining by nearly 5% each.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.68% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, declined 1.28%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, fell 0.2%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Wednesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were down over 5% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-s-ai-expansion-hits-snag-as-key-investor-pulls-back-report/cLeO1HSREqa">faced</a> a setback in its AI data center expansion efforts after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/HUT">Hut 8 Corp. (HUT)</a>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hut-shares-soar-over-24-percet-today-whats-the-deal-involving-google-and-anthropic/cLeO1aZREqJ">announced</a> that it is building an AI data center for Anthropic, and that it had signed a 15-year, $7 billion lease with Fluidstack. The company added that the lease would be worth up to $17.7 billion if all renewal options are exercised.<a href="https://stocktwits.com/symbol/HUT">HUT stock</a> is up 100% year-to-date.<a href="https://stocktwits.com/symbol/PCSA">Processa Pharmaceuticals Inc. (PCSA)</a>Processa Pharmaceuticals share price nearly doubled, hovering at gains of 95% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-processa-pharmaceuticals-stock-surge-160-today/cLeOVJlREqV">stated</a> that its early Phase 2 trial data showed that its NGC-Cap therapy significantly increases exposure to capecitabine cancer-killing drug metabolites without increasing the severity of side effects compared to standard monotherapy capecitabine therapy.<a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> is down 73% year-to-date.<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals Inc. (RXRX)</a>Recursion Pharmaceuticals shares were up over 16% in Wednesday’s midday session after Morgan Stanley upgraded the stock to ‘Overweight’ from ‘Neutral’, according to TheFly. The firm also hiked its price target for the RXRX stock to $11 from $10, citing “strong and durable” efficacy in familial adenomatous polyposis from the company's small-molecule drug, REC-4881.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 28% year-to-date.<a href="https://stocktwits.com/symbol/UDMY">Udemy Inc. (UDMY)</a>Udemy shares were up more than 22% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cour-udmy-stock-premarket-coursera-udemy-announce-merger/cLeOKUtREq4">announced</a> a merger with Coursera Inc. (COUR), with an implied equity value of the combined entity of approximately $2.5 billion.<a href="https://stocktwits.com/symbol/UDMY">UDMY stock</a> is down 20% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/waller-fed-chair-odds-surge-after-dovish-comments/cLeOjlBREqg">Waller's Odds For Fed Chair Nomination Surge After The Fed Governor's Dovish Comments On Rate Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

<ul class="summary-bullets"><li>Processa plans to complete enrollment for the formal 20-patient interim analysis by the end of the first quarter of 2026.</li><li>The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday.</li><li>Trading in PCSA shares was halted multiple times today, according to Nasdaq data.</li></ul>Processa Pharmaceuticals Inc. (PCSA) surged over 160% on Wednesday, after the company announced that early Phase 2 data showed that its Next Generation Cancer (NGC) therapy delivered higher levels of cancer-fighting metabolites in patients with advanced or metastatic breast cancer.The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday. Trading in <a href="https://stocktwits.com/symbol/PCSA">PCSA shares</a> was halted multiple times on Wednesday, according to Nasdaq data.<h2 class="st-heading-2">Phase 2 Study Results&nbsp;</h2>Preliminary data from the first 16 of 19 enrolled patients indicated that NGC-Cap significantly increases exposure to capecitabine’s cancer-killing metabolites compared with standard capecitabine monotherapy without increasing the severity of side effects seen with standard treatment. The company believes the balance could improve outcomes for patients with advanced breast cancer.Nineteen patients were randomized to receive either NGC-Cap (150 mg twice daily) or standard Mono-Cap (1,000 mg/m² twice daily). Early safety data from the first 16 patients show higher exposure to cancer-killing metabolites in the NGC-Cap group.While more patients in the NGC-Cap group experienced side effects related to these metabolites, the severity was similar to that in the Mono-Cap group.&nbsp;Processa plans to complete enrollment for the formal 20-patient interim analysis, which will include both safety and efficacy data, by the end of the first quarter of 2026. The company expects to report the interim analysis in early 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’, amid ‘extremely high’ message volumes. PCSA was the top trending ticker on Stocktwits.<figure class="image"><img style="aspect-ratio:922/93;" src="https://news.stocktwits-cdn.com/PCSA_png_df422e4216.webp" alt="PCSA.png" width="922" height="93"><figcaption>PCSA's Sentiment Meter and Message Volumes at 11:30 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>One Stocktwits user expects further upside to the stock.<stembedurl>https://stocktwits.com/AJWW316/message/639440673</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uwm-holdings-to-acquire-two-harbors-investment-in-1-3-b-deal/cLeOjLYREqf">UWM Holdings To Acquire Two Harbors Investment In $1.3B Deal - How Much Of The Combined Company Will UWM Shareholders Own?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Why Did Processa Pharmaceuticals Stock Surge 160% Today?

The company announced that early Phase 2 data showed that its NGC therapy increased cancer-fighting metabolites in patients with advanced breast cancer.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

PCSA
Processa Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PCSA News

PCSAProcessa Pharmaceuticals Inc